Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
53 hedge funds and large institutions have $53.1M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 20 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
4% more funds holding
Funds holding: 51 → 53 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
54% less capital invested
Capital invested by funds: $115M → $53.1M (-$61.8M)
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$114K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$101K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.3K |
| 4 |
BlackRock
New York
|
+$70.4K |
| 5 |
Renaissance Technologies
New York
|
+$56.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$5.98M |
| 2 |
LSCM
Light Street Capital Management
Palo Alto,
California
|
-$1.1M |
| 3 |
E
Ergoteles
New York
|
-$345K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$135K |
| 5 |
Millennium Management
New York
|
-$126K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $2K | -$12K | -52 | -83% |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$9K | -39 | -71% |
|
|
53
Millennium Management
New York
| – | -$126K | -421 | Closed |
|
54
Lazard Asset Management
New York
| – | -$1K | -5 | Closed |
|
55
Fidelity Investments
Boston,
Massachusetts
| – | +$462 | +2 | New |
|
FNCH Hedge Fund Activity: Q1 2022 in Review
53 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q1 2022, worth a combined $53.1M — down 54% from $115M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FNCH positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 20 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $114K. The largest seller was MSD Partners, cutting an estimated $5.98M.
- 53 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q1 2022, up from 51 in Q4 2021.
- Funds reported $53.1M of Finch Therapeutics Group, Inc. Common Stock stock for Q1 2022, down 54% quarter-over-quarter.
- 4 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q1 2022 and 2 closed out, a net change of +2 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q1 2022 was Ikarian Capital, an estimated $114K added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q1 2022 was MSD Partners, an estimated $5.98M sold.
Based on aggregated 13F filings for Q1 2022.